Beyond its well-established role in suppressing tumor initiation, evidence suggests that SIRT7 retains tumor-suppressive activity only in a limited subset of malignancies—such as breast cancer—or in tumors characterized by specific genomic alterations, though this remains to be conclusively demonstrated (Table 1). Here, SIRT7 is linked to breast carcinoma.